Coventry patients harmed by prolonged chemotherapy, review finds


The Royal College of Physicians found treatment continued without evidence of benefit at an NHS trust and rated 15 of 20 cases unsatisfactory; it recommends further independent reviews.
Some brain tumor patients at University Hospitals Coventry and Warwickshire NHS Trust were harmed after receiving prolonged chemotherapy without evidence that continuing it would help, a Royal College of Physicians review found.
The trust commissioned the review after colleagues raised concerns when clinical oncologist Professor Ian Brown’s patients were handed over following his retirement in 2023. The review found that some patients had been misdiagnosed and given inappropriate treatment, while others were wrongly told they would die if they stopped chemotherapy.
Of the 20 cases examined, 15 were rated unsatisfactory overall and five required improvement; none was rated good practice. The report considered the potential harm severe in 6 cases.
The drug, temozolomide, is used to treat brain tumors. A standard regimen for newly diagnosed glioblastoma, an aggressive brain tumor, combines it with radiotherapy and follows with up to six maintenance cycles.
Law firm Brabners said the cases selected for the initial review involved patients who received more than 12 cycles between 2017 and 2023. The review also found that some patients stayed on treatment as their cancer progressed, when care to relieve their symptoms would have been a better choice.
The review found concerns in all the cases about how consent was obtained and treatment explained. Brabners said reviewers found no evidence that patients were routinely told their treatment was outside recognized standards, and little evidence they were warned of long-term risks.

Yvette Cooper says joint health and social-care teams aim to reach that initial target by April 2027, with an eventual ambition of supporting 2 million people.
The review found no evidence of effective challenge from the wider care team, including nursing and pharmacy staff, and said opportunities to question unusual treatment decisions were missed.
Former patient Becky Jones received more than 100 chemotherapy cycles over 10 years after an incorrect glioblastoma diagnosis, The Guardian said. Jones said she had questioned why treatment continued when her scans were stable and had been told she would die without it. She said she needed a full and honest explanation of what happened to her.
Trust chief executive Andy Hardy and chair Sue Noyes apologized to patients and families affected by failures in the brain tumor service under Brown’s care. They said the trust had extended its historical review back to 2005 to identify and support affected patients.
Brabners said Brown did not engage with the review. The firm said the review recommended that the trust consider sharing its findings with the General Medical Council and consider whether a further regulatory referral concerning former clinical nurse specialist Ian Edwards was warranted.
The Royal College recommends an independent review for every living patient who received more than 12 cycles of temozolomide, and says the trust should consider reviewing patients who have since died and received the same non-standard treatment. Brabners, which represents more than 40 patients, is calling for an independent public inquiry.
2 min

The predicted crossing would make the probe the first human-made object to reach that distance; a signal expected about a day later is needed to confirm it.
2 min

Andrew Macintosh’s team says tree cover increased only slightly over five wet years in areas used to generate carbon credits. Project developers dispute the findings.
3 min